JPRN-UMIN000005488已完成未知
Examination of Effectiveness, safety, of Cetuximab as 1st-line treatment for KRAS wild type colorectal cancer. - Examination of Effectiveness, safety, of Cetuximab as 1st-line treatment for KRAS wild type colorectal cancer.
Multicenter Clinical Study Group Osaka Colorectal Cancer Treatment Group0 个研究点目标入组 100 人开始时间: 2011年4月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
Response rate
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who are inadequate by investigator's decision.
研究者
相似试验
已完成
不适用
Safety assessment of treatment with cetuximab in metastatic colorectal cancer patientsMetastatic colorectal cancerMalignant neoplasm of other and ill-defined digestive organsCancerISRCTN34968597Institute of Oncology Ljubljana (Slovenia)250
已完成
2 期
Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT00251498Veeda Oncology82
终止
2 期
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without BevacizumabColorectal NeoplasmsNCT00321100Fox Chase Cancer Center23
进行中（未招募）
不适用
A Stratified Phase II Study of Cetuximab (ErbituxTM) for the Treatment of Recurrent Glioblastoma Multiforme / Estudio de fase II estratificado de cetuximab para el tratamiento del glioblastoma multiforme recidivante - Cetuximab for recurrent GBMpatients with a recurrent glioblastoma multiforme following preceding surgery, radiation therapy and chemotherapyEUCTR2005-000459-14-ESOncologisch Centrum, Academisch Ziekenhuis Vrije Universiteit Brussel54
已完成
2 期
Phase II Study in Patients With Recurrent Non-Small-Cell Lung CancerNon-Small-Cell Lung CancerNCT00063388Eli Lilly and Company66